Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Newly synthesized Mpro inhibitors as potential oral anti-SARS-CoV-2 agents

Fig. 1

Anti-SARS-CoV-2 efficacy of Mpro inhibitors in a hACE2 transgenic mouse model. (a, b) Chemical structures of MI-09 and MI-30. c MI-09 (i.p. or p.o.) and MI-30 (i.p.) treatments inhibit SARS-CoV-2 viral replication, suppress SARS-CoV-2-induced infiltration of immune cells (neutrophils and macrophages) and secretion of IFN-β and CXCL10 in lung tissues, and reduce SARS-CoV-2-induced lung lesions in hACE2 transgenic mice

Back to article page